DiscoverExpert Voices in DementiaReal-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab
Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Update: 2024-07-15
Share

Description

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Comments 
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

2024-11-1915:41

BrainCheck as a Digital Cognitive Assessment Tool

BrainCheck as a Digital Cognitive Assessment Tool

2024-11-0807:17

Kramer, Van Dyck

Kramer, Van Dyck

2024-09-2712:18

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

2024-09-2110:14

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

2024-09-2117:02

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

2024-09-2108:53

Labcorp's Biomarker Testing for Alzheimer Disease

Labcorp's Biomarker Testing for Alzheimer Disease

2024-09-1612:50

What Neurologists Should Know About End-of-Life Care Discussions

What Neurologists Should Know About End-of-Life Care Discussions

2024-07-1920:47

Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

2024-07-1522:07

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

2024-07-1509:22

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

2024-07-1508:51

Emerging Therapeutic Targets for Alzheimer Disease

Emerging Therapeutic Targets for Alzheimer Disease

2024-07-1514:27

Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia

Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia

2024-07-0713:05

How Healthcare Providers Can Partner with Caregivers of People Living with Dementia

How Healthcare Providers Can Partner with Caregivers of People Living with Dementia

2024-07-0718:10

Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Practical Neurology